Learn more about the importance of early diagnosis and treatment from a keratoconus patient and her treating physician.
Patient Perspective on Cross-Linking
A General Overview
Corneal cross-linking is a minimally invasive outpatient procedure that combines the use of Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution), Photrexa® (riboflavin 5’-phosphate ophthalmic solution) and the KXL® system for the treatment of progressive keratoconus.
- Creates new corneal collagen cross-links
- Results in a shortening and thickening of the collagen fibrils
- Leads to the stiffening of the cornea
The first and only therapeutic products for corneal cross-linking which have been FDA approved to treat progressive keratoconus.
In April 2016, the FDA approved Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution) and Photrexa® (riboflavin 5’-phosphate ophthalmic solution) and the KXL® System for corneal cross-linking, a minimally invasive outpatient procedure that combines the use of Vitamin B2 eye drops and ultra-violet (UV) light.
The approval of Photrexa Viscous, Photrexa and the KXL System offers an effective treatment for patients who, until recently, had no therapeutic options to limit the progression of this sight-threatening disease.
Learn more about this outpatient procedure
View our Living with Keratoconus Patient Brochure.
Discover answers to the most common questions surrounding cross-linking
Visit the Patient FAQ Section to learn more.
It is estimated that...
1 Out of Every 2,000
persons in the general population have Keratoconus1
You can find more information from the National Keratoconus Foundation.
1. Kennedy R. H., Bourne W. M., Dyer J. A. A 48-year clinical and epidemiologic study of keratoconus. The American Journal of Ophthalmology. 1986;101(3):267–273. doi: 10.1016/0002-9394(86)90817-2.
Corneal cross-linking provides patients a much-needed option to treat this debilitating disease. Patients suffering from progressive keratoconus can now receive a therapeutic treatment that has been rigorously tested and approved."Mary Prudden, Executive Director for the National Keratoconus Foundation